Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272956 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL5403510 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL2848716 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL15307926 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL30513444 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL14606172 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL3551562 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL15746874 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL15746882 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 | |
| SCHEMBL3554038 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1LMNANPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052497-B1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE | WOCKHARDT LTD (IN) | 2017-06-28 | — | — | EP | disclosed |
| EP-1497273-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-7589091-B2 | 2(R)-Benzyloxymethyl-4-[4-(4-chloro-phenyl)-piperazin-1-yl]-N-hydroxy-3(S)-(4-methoxy-phenyl)-4-oxo-butyramide; inhibiting matrix metalloproteinase; immunosuppression; neuropathic pain | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20060063778-A1 | Hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-03-23 | — | — | US | disclosed |
| US-5571832-A | Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063778-A1 | Hydroxamic acid derivatives | HCAR1, HCAR2, TNF | SMN1; SMN2 3396/4885NPC1 4604/4885LMNA 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.